Amgen’s Tavneos troubles continue as NEJM retracts pivotal publication
Earlier this year, Amgen refused the FDA’s request to withdraw Tavneos from the market. Now, two researchers who participated in the original study to support the drug’s approval claim they did not know the primary endpoint was readjudicated after the study was unblinded.
Amgen’s Tavneos troubles continue as NEJM retracts pivotal publication Read More »
